Omeros Corporation (NASDAQ:OMER – Get Free Report) shares crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $13.80 and traded as low as $13.07. Omeros shares last traded at $13.21, with a volume of 2,019,480 shares.
Omeros News Summary
Investors following OMER have been watching these news items:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $33 price target, raising its FY2026 EPS estimate to a loss of $0.08 per share from a loss of $0.37, and increasing its FY2029 and FY2030 forecasts. Analyst forecasts for Omeros
- Positive Sentiment: Cantor Fitzgerald reiterated a Buy rating, adding to the positive analyst commentary. Cantor Fitzgerald remains a Buy
- Positive Sentiment: An earnings-call report highlighted growth for YARTEMLEA, which may support investor optimism about the product’s commercial prospects. Omeros earnings call highlights YARTEMLEA growth
Analyst Ratings Changes
A number of brokerages have commented on OMER. HC Wainwright restated a “buy” rating and issued a $33.00 price target on shares of Omeros in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $22.00 price target on shares of Omeros in a research report on Wednesday, October 14th. Weiss Ratings upgraded Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen downgraded Omeros from a “buy” rating to a “hold” rating in a report on Saturday. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and a consensus price target of $30.33.
Omeros Price Performance
The firm has a market capitalization of $956.27 million, a PE ratio of 13.76 and a beta of 2.96. The company has a fifty day moving average of $17.83 and a 200-day moving average of $13.80.
Omeros (NASDAQ:OMER – Get Free Report) last posted its earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04. The firm had revenue of $35.93 million during the quarter, compared to the consensus estimate of $37.28 million. Equities analysts anticipate that Omeros Corporation will post -0.08 EPS for the current year.
Insider Activity at Omeros
In other Omeros news, Director Arnold Hanish sold 10,000 shares of the company’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at $94,750. This represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO David Borges sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total transaction of $209,500.00. Following the sale, the chief accounting officer directly owned 5,000 shares in the company, valued at $104,750. The trade was a 66.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 75,906 shares of company stock valued at $1,438,705. 10.50% of the stock is owned by insiders.
Institutional Trading of Omeros
Several large investors have recently added to or reduced their stakes in the business. Algert Global LLC purchased a new stake in Omeros during the third quarter valued at approximately $1,234,000. New York State Common Retirement Fund lifted its stake in Omeros by 25.6% in the 3rd quarter. New York State Common Retirement Fund now owns 26,013 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 5,300 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Omeros in the third quarter valued at approximately $733,000. Goldman Sachs Group Inc. increased its holdings in Omeros by 151.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 395,032 shares of the biopharmaceutical company’s stock valued at $7,521,000 after purchasing an additional 238,024 shares during the last quarter. Finally, Empowered Funds LLC purchased a new position in Omeros in the third quarter valued at $3,387,000. 48.79% of the stock is currently owned by institutional investors.
Omeros Company Profile
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
Featured Articles
- Five stocks we like better than Omeros
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
